Atazanavir or Lopinavir in HIV Post-exposure Prophylaxis

Summary

The study compares the adherence of 240 HIV-negative subjects randomly assigned to 2 different antiretroviral therapies for 28 days after accidental exposure to HIV.

Timeline

Start

2006-05

Primary completion

2009-08

Completion

2009-08

Outcome

Missed primary endpoint

paper The rate of discontinuation before day 28 owing to any cause was similar between groups (37/102 [36%] in lopinavir/ritonavir and 35/98 [36%] in atazanavir arms, P=0.82). PMID 22293542 ↗

paper The rate of discontinuation of PEP before day 28 was similar with zidovudine/lamivudine plus either lopinavir/ritonavir or atazanavir. PMID 22293542 ↗

Publications

• Diaz-Brito V, Leon A, Knobel H, Peraire J, Domingo P, Clotet B, Dalmau D, Cruceta A, Arnaiz JA, Gatell JM, Garcia F; DATEMPEP study group. Post-exposure prophylaxis for HIV infection: a clinical trial comparing lopinavir/ritonavir versus atazanavir each with zidovudine/lamivudine. Antivir Ther. 2012;17(2):337-46. doi: 10.3851/IMP1955. Epub 2011 Nov 25.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Atazanavir	Other / unclassified	—	—
Subject	Combivir	Unknown	—	—
Subject	Kaletra	Unknown	—	—

Indications